Cannabis Compounds Show Promise for Treating Fatty Liver Disease
Finn's Take· TL;DR- CBD and CBG compounds reduced liver fat, improved blood sugar control, and lowered harmful lipids in obese mice models.
- Compounds work by boosting cellular energy and restoring enzyme function, helping the liver clear damaging fats without causing intoxication.
- Human trials still needed before these cannabis-derived treatments can treat fatty liver disease, which affects roughly one-third of adults globally.
Revolutionary Discovery in Liver Disease Treatment
A groundbreaking study from Hebrew University of Jerusalem has revealed that two non-intoxicating cannabis compounds, CBD and CBG, can improve blood sugar control, reduce liver fat, and lower blood lipid levels in obese mice . This research offers hope for millions suffering from metabolic dysfunction-associated steatotic liver disease (MASLD), commonly known as fatty liver disease.
MASLD has become the most common chronic liver disorder in the world, impacting roughly a third of the global adult population . Despite its prevalence, no pharmacological treatments have been approved to date , leaving patients with limited options beyond lifestyle changes.
How Cannabis Compounds Target Liver Health
The study, published in the British Journal of Pharmacology, uncovered a fascinating mechanism behind the compounds' effectiveness. These compounds increase levels of phosphocreatine, which acts like a backup battery to help the liver stay healthy under the stress caused by a high-fat diet . This is a new discovery, as the liver does not usually rely heavily on this specific energy system .
The researchers also found that CBD and CBG restore the activity of cathepsins - enzymes that act like a "cleaning crew" within the cell's recycling centres, known as lysosomes . By getting this cleaning crew back to work, the liver is better able to break down and clear out harmful fats and waste .
CBG proved particularly effective, reducing body fat, lowering 'bad' cholesterol, and increasing insulin sensitivity in obese mice significantly more than CBD .
Targeting Dangerous Fat Molecules
The researchers observed major reductions in damaging lipid molecules including triglycerides and ceramides . Ceramides are especially harmful because they are linked to insulin resistance and inflammation in the liver .
Neither CBD nor CBG seems to be active in the central nervous system (at least not in their purest form), which means on their own they don't trigger a 'high' in human patients like THC does. This is another benefit to their potential use as medicine .
The Path to Human Treatment
While these findings represent a significant breakthrough, researchers emphasize caution. Experts caution that these findings are still preclinical, meaning they were observed in controlled laboratory models. Human clinical trials will be necessary before cannabis-derived therapies could become standard treatments .
Professor Joseph Tam, who led the research, expressed his hope "to bring a cannabinoid-based drug to help the human population suffering from fatty liver disease and metabolic disorder" . The potential impact could be enormous, given that fatty liver disease affects one in three adults worldwide and currently has no approved pharmaceutical treatment.
This research opens new possibilities for plant-based medicine in treating metabolic disorders. As scientists continue exploring cannabis compounds beyond THC, we may be witnessing the beginning of a new era in liver disease treatment that harnesses the therapeutic potential of nature's pharmacy.